| Target Price | $76.50 |
| Price | $70.86 |
| Potential |
7.96%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 .
The average Ionis Pharmaceuticals, Inc. target price is $76.50.
This is
7.96%
register free of charge
$100.80
42.25%
register free of charge
$43.43
38.71%
register free of charge
|
|
| A rating was issued by 31 analysts: 23 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
7.96%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 705.14 | 874.46 |
| 10.48% | 24.01% | |
| EBITDA Margin | -65.68% | -42.64% |
| 61.22% | 35.08% | |
| Net Margin | -64.37% | -47.33% |
| 38.42% | 26.47% |
28 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
29 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.04 | -2.60 |
| 18.75% | 14.47% | |
| P/E | negative | |
| EV/Sales | 11.73 |
29 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Ionis Pharmaceuticals, Inc....
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 08 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Oct 06 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 08 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 08 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 08 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Oct 06 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


